Review of TOUCH CMCJ arthroplasty outcomes in Aotearoa New Zealand
Tracks
Hand Surgeon Talk
| Saturday, October 17, 2026 |
| 2:30 PM - 2:40 PM |
| Rongomātāne Hall C, Tākina |
Overview
Darina Gilroy
Details
Aims
Basilar thumb arthritis is a common disorder affecting up to 40% of older adults. The disease impacts the ability to perform activities of daily living due to pain, restricted range of motion and reduced grip and pinch strength. Treatment options include excision arthroplasty, fusion, and more recently, carpometacarpal joint (CMCJ) replacement. CMCJ replacements have become an increasingly popular option for patients with Eaton-Littler stage 1-3 disease with promising short- to medium-term outcomes in publications from Europe. The TOUCH® dual-mobility CMCJ prosthesis has been used in Aotearoa New Zealand since 2023.
The aim of this study is to report the clinical, functional and radiographic outcomes of patients undergoing CMCJ replacement in Aotearoa New Zealand.
Methods This study will constitute a retrospective cohort review of the outcomes of patients undergoing surgery by four surgeons at five hospitals across New Zealand. Inclusion criteria are any patient undergoing CMCJ arthroplasty over the age of 18 who have consented to participate. The primary outcomes to be assessed will be implant survival and adverse events based on the Clavien-Dindo scale. Secondary endpoints will include hand function as assessed by range of motion, pain, functional scores including QuickDASH and PRWE, and radiographic outcomes. We will additionally collect data on ethnicity, gender, age, occupation and handedness. This is intended to be the first comprehensive review in New Zealand of thumb CMCJ replacements. Results and conclusions to follow.
Methods This study will constitute a retrospective cohort review of the outcomes of patients undergoing surgery by four surgeons at five hospitals across New Zealand. Inclusion criteria are any patient undergoing CMCJ arthroplasty over the age of 18 who have consented to participate. The primary outcomes to be assessed will be implant survival and adverse events based on the Clavien-Dindo scale. Secondary endpoints will include hand function as assessed by range of motion, pain, functional scores including QuickDASH and PRWE, and radiographic outcomes. We will additionally collect data on ethnicity, gender, age, occupation and handedness. This is intended to be the first comprehensive review in New Zealand of thumb CMCJ replacements. Results and conclusions to follow.